Similar to previous studies, BRAF/MEKi induces a rapid tumor reduction within the first few days, which then leads to a plateau phase (drug‐tolerant, residual disease) after ≈2 weeks of treatment.[2, 13] With continued BRAF/MEKi treatment, tumors develop full resistance and rebound to their initial size (i.e., ≈700mm3 in size) at ≈3 to 4 weeks of BRAF/MEKi administration (Figure1A; Figure S1A, Supporting Information). The gene discussed is BRAF; the disease is neoplasm.